The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I think some people may have taken the impression from AN's interview that it will be years before anything material happens. It will certainly be the case that it will take years to grab enough market to become a massive company ($10bln plus), but in short / medium term plenty of things will happen (contracts, partnerships etc) that start the journey to get there, and these will materially increase the value of the company.
The diminishing level of month on month production decreases over the last 4 months has been very promising. If the production update on circa 17th June indicates that the production has continued to stabilise around 9000 bpd then the well could have years of life ahead of it.
Won't be long before folks start to realise that this is a cash cow.
I wonder if these changes will negate the need for a phase 1/2 in the UK. If so that is very good news as we will be able to progress to phase III (in partnership) in H1 2023. Bermudashorts or Burble's opinion on this would be very welcome.
Interesting tweet from Angle:-
'Find #ANGLE at Precision Med Expo & Summit from 24-25th May where we will be joining Integrated Gulf Biosystems on stand C06 to demonstrate our patented #Parsortix® technology. (For Research Use Only. Not For Use in Diagnostic Procedures) Visit hxxps://precisionmedexpo.com'
https://twitter.com/Parsortix/status/1528780119678062592
I wonder if we about to see another partnership being announced ?
Hi BucksLad
'Clearly Angle board assumes its now just a buereaucratic delay caused by initial lack of reagents and covid absences at the FDA labs and office.'
The lack of reagents has nothing to do with the FDA approval. It relates to the analysis of the samples in the ovarian trial. Regarding the FDA labs, I am not aware that the FDA are undertaking their own hands on trial of Parsortix and the company have never indicated that this is taking place, so I think you are perhaps mistaken on this. The impact of Covid has no doubt delayed things.
Looks to me like the page was created by this lady who is looking to address the lack of female scientists covered on Wikipedia ;-
https://en.wikipedia.org/wiki/Jess_Wade
The fact that Scancell are presenting their Glycan/Avidimab (Glmab) portfolio at such a prestigious conference must indicate that they are now very confident in the platform. They are putting their goods in the shop window - ready for deals to be done.
Kashdog, scousemark, Balckfordian - thanks for your replies. I guess that the upside of doing the drawdown from the SIPP and using the cash to buy shares in the ISA is that when the value of the SIPP is next assessed (for tax purposes) it would minimise the risk of the SIPP being over the lifetime allowance if the Scancell shares appreciate greatly in value ?